Research Topic: EEG

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review

mycolabadmin

This review examines how scientists can predict which patients will benefit most from psychedelic-assisted therapy for depression by measuring biological markers in the brain and blood. Researchers found that certain brain changes and protein levels—particularly involving the amygdala, specific brain regions, and inflammation markers—appear linked to treatment success. While the current studies are small, they suggest that measuring these biological markers could eventually help doctors personalize psychedelic treatments for depression.

Read More »

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

mycolabadmin

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

mycolabadmin

Researchers tested how different psychedelic drugs affect brain electrical activity in rats using EEG recordings. They found that psilocin, LSD, mescaline, and DOB all produced similar patterns of decreased brain activity and reduced communication between brain regions. Importantly, these effects in rats closely matched what scientists observe in human brain studies, suggesting that rats can be useful for understanding how psychedelics work in the brain.

Read More »
Scroll to Top